These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 9723272)
41. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients. Gaston R; Alloway RR; Gaber AO; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; First MR Transplant Proc; 1999; 31(1-2):326-7. PubMed ID: 10083128 [No Abstract] [Full Text] [Related]
42. Case study: de novo application of Neoral in renal transplantation. Kahan BD Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196 [No Abstract] [Full Text] [Related]
43. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients. Tsang WK; Ho YW; Tong KL; Chan WH; Chan A Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681 [No Abstract] [Full Text] [Related]
44. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy. Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101 [No Abstract] [Full Text] [Related]
45. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Shah MB; Martin JE; Schroeder TJ; First MR Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291 [No Abstract] [Full Text] [Related]
46. Neoplanta as a new microemulsion formula of cyclosporine in renal transplantation: comparative study with Neoral for efficacy and safety. Kim SC; Han DJ Transplant Proc; 1998 Nov; 30(7):3547-8. PubMed ID: 9838552 [No Abstract] [Full Text] [Related]
47. Time-dependent difference of the 12-hour trough levels of cyclosporine in renal transplant recipients with sandimmune capsule. To H; Haba T; Uchida K; Fujimura A; Kobayashi E Transplant Proc; 2000 Feb; 32(1):221-2. PubMed ID: 10701028 [No Abstract] [Full Text] [Related]
49. Clinical impact of Neoral in thoracic organ transplantation. Aziz T; el-Gamel A; Keevil B; Krysiak P; Campbell C; Rahman A; Deiraniya A; Yonan N Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326 [No Abstract] [Full Text] [Related]
50. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. Einecke G; Mai I; Diekmann F; Fritsche L; Neumayer HH; Budde K Transplant Proc; 2002 Aug; 34(5):1738-9. PubMed ID: 12176557 [No Abstract] [Full Text] [Related]
51. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients. Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366 [No Abstract] [Full Text] [Related]
52. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245 [No Abstract] [Full Text] [Related]
53. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients. Crocker J; Renton K; Wade A; McLellan H; Acott P Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369 [No Abstract] [Full Text] [Related]
55. Neoral C2 monitoring in solid organ transplantation. Levy GA Transplant Proc; 2004 Mar; 36(2 Suppl):392S-395S. PubMed ID: 15041373 [No Abstract] [Full Text] [Related]
56. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338 [No Abstract] [Full Text] [Related]
57. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant. Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892 [No Abstract] [Full Text] [Related]
58. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249 [No Abstract] [Full Text] [Related]
59. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients. Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560 [No Abstract] [Full Text] [Related]
60. Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience. Goh BL; Jalil R; Koh SN; Chua CT; Tan SY Transplant Proc; 1998 Nov; 30(7):3535-6. PubMed ID: 9838548 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]